These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16525668)

  • 1. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
    Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
    Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
    Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
    Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
    Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
    Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
    Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
    Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
    Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
    Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
    Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
    Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
    Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
    Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
    Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
    Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
    Zastre J; Anantha M; Ramsay E; Bally M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):91-102. PubMed ID: 17009029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
    Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
    Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.
    Shishido Y; Furuta T; Matsuzaki T; Nagata H; Hashimoto S
    Biol Pharm Bull; 2010; 33(7):1183-91. PubMed ID: 20606311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.